Quantcast

Latest Olaparib Stories

2012-01-12 11:32:45

After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease. A report on the discovery was published in the January 12, 2012 issue of the New England Journal of Medicine. UNC-Chapel Hill scientist Ethan Lange, PhD, was part of the team of investigators at the Johns Hopkins University School of Medicine, the University of...

2011-12-12 23:35:09

Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells to repair broken bits of their own DNA, causing these cells to self-destruct. Results of their experiments, expected to be presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, Dec. 12, have already prompted clinical trials of the drugs in patients with...

2011-11-01 05:57:36

(Ivanhoe Newswire) — The largest study of its kind shows that women related to a patient with breast cancer caused by a hereditary mutation, but who don´t have the mutation themselves, have no higher risk of developing cancer than relatives of patients with other types of breast cancer. This contradicts previous research conducted four years ago that said that a familial BRCA mutation in and of itself was a risk factor. "The results are encouraging and reassuring," Allison...

2011-10-12 10:40:04

DNA-damaging platinum drugs work better against them; BRCA1 variations have no effect Women with high-grade ovarian cancer live longer and respond better to platinum-based chemotherapy when their tumors have BRCA2 genetic mutations, researchers at The University of Texas MD Anderson Cancer Center and the Institute for Systems Biology report in the Oct. 12 issue of the Journal of the American Medical Association. "BRCA2-mutated tumors are more vulnerable to these DNA-damaging agents,...

2011-10-12 10:35:42

Among women with a certain type of high-grade ovarian cancer, having BRCA2 genetic mutations, but not BRCA1, was associated with improved overall survival and improved response to chemotherapy, compared to women with BRCA wild-type (genetic type used as a reference to compare genetic mutations), according to a study in the October 12 issue of JAMA. "Increased surveillance of BRCA1/2 germ line mutation carriers is a generally accepted strategy for detecting early ovarian cancer. Women with...

2011-06-02 14:17:00

BOULDER, Colo., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. announced today an agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of Pfizer's oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, currently in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the...

2011-05-18 13:54:29

About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study from the University of Michigan Comprehensive Cancer Center finds. The drugs, called PARP inhibitors, are currently being tested in breast cancer patients with mutations in the BRCA1 and BRCA2 genes, which are found in up to 10 percent of all breast cancers. Half of prostate cancers have a genomic rearrangement that causes the fusion of two...

2011-04-25 14:54:44

15 percent of colorectal cancers have mutation that responds to PARP inhibitors A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds. Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations...

2011-04-04 19:37:00

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation. In results presented at the AACR 102nd Annual Meeting 2011, held April 2-6, Kelly Bolton, a fellow at the National Cancer Institute, said the findings describe the effect of these mutations in ovarian cancer survival. "There was some previous evidence that women with ovarian cancer who have mutations in the BRCA genes show...

2010-11-15 16:36:51

New research from the Centenary Institute finds a new death pathway that can break resistance Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related